Cargando…

Clinical and immunohistochemical study of eight cases with thymic carcinoma

BACKGROUND: Thymic carcinoma is a rare neoplasm with extremely poor prognosis. To evaluate the biological characteristics of thymic carcinoma, we reviewed 8 patients. METHODS: There were 2 men and 6 women: ages ranged from 19 to 67 years old (mean 54.8 years). None of these patients had concomitant...

Descripción completa

Detalles Bibliográficos
Autores principales: Tomita, Masaki, Matsuzaki, Yasunori, Edagawa, Masao, Maeda, Masayuki, Shimizu, Tetsuya, Hara, Masaki, Onitsuka, Toshio
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2002
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC115847/
https://www.ncbi.nlm.nih.gov/pubmed/12049674
http://dx.doi.org/10.1186/1471-2482-2-3
_version_ 1782120251905802240
author Tomita, Masaki
Matsuzaki, Yasunori
Edagawa, Masao
Maeda, Masayuki
Shimizu, Tetsuya
Hara, Masaki
Onitsuka, Toshio
author_facet Tomita, Masaki
Matsuzaki, Yasunori
Edagawa, Masao
Maeda, Masayuki
Shimizu, Tetsuya
Hara, Masaki
Onitsuka, Toshio
author_sort Tomita, Masaki
collection PubMed
description BACKGROUND: Thymic carcinoma is a rare neoplasm with extremely poor prognosis. To evaluate the biological characteristics of thymic carcinoma, we reviewed 8 patients. METHODS: There were 2 men and 6 women: ages ranged from 19 to 67 years old (mean 54.8 years). None of these patients had concomitant myasthenia gravis and pure red cell aplasia. No patient had stage I disease, 1 stage II, 5 stage III, and 2 stage IV. The pathologic subtypes of thymic carcinoma included 5 squamous cell carcinomas, 1 adenosquamous cell carcinomas, 1 clear cell carcinoma, and 1 small cell carcinoma. Immunohistochemical study was performed using antibodies against p53, bcl-2, Ki-67, carcinoembryonic antigen (CEA), epithelial membrane antigen (EMA), nm23-H1, vascular endothelial growth factor (VEGF), basic fibroblast growth factor (FGF-2) and factor VIII. RESULTS: Curative resection could be done in 4 patients (50%). Our data indicates a trend toward an association between complete resection and patient survival. Expression of p53, bcl-2, CEA, EMA, nm23-H1, VEGF and FGF-2 was detected in 5/8, 3/8, 4/8, 5/8, 6/8, 5/8 and 3/8, respectively. Mean Ki-67 labeling index and microvessel density was 7.01 and 34.36 (per 200× field), respectively. When compared with our previous studies, immunohistochemical staining of these proteins in thymomas, the expression rates of these proteins in thymic carcinomas were higher than those in thymomas. CONCLUSIONS: In this small series, it is suggested that a complete resection suggests a favorable result. Immunohistochemical results reveal that the expression of these proteins might indicate the aggressiveness of thymic carcinoma.
format Text
id pubmed-115847
institution National Center for Biotechnology Information
language English
publishDate 2002
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-1158472002-06-14 Clinical and immunohistochemical study of eight cases with thymic carcinoma Tomita, Masaki Matsuzaki, Yasunori Edagawa, Masao Maeda, Masayuki Shimizu, Tetsuya Hara, Masaki Onitsuka, Toshio BMC Surg Research Article BACKGROUND: Thymic carcinoma is a rare neoplasm with extremely poor prognosis. To evaluate the biological characteristics of thymic carcinoma, we reviewed 8 patients. METHODS: There were 2 men and 6 women: ages ranged from 19 to 67 years old (mean 54.8 years). None of these patients had concomitant myasthenia gravis and pure red cell aplasia. No patient had stage I disease, 1 stage II, 5 stage III, and 2 stage IV. The pathologic subtypes of thymic carcinoma included 5 squamous cell carcinomas, 1 adenosquamous cell carcinomas, 1 clear cell carcinoma, and 1 small cell carcinoma. Immunohistochemical study was performed using antibodies against p53, bcl-2, Ki-67, carcinoembryonic antigen (CEA), epithelial membrane antigen (EMA), nm23-H1, vascular endothelial growth factor (VEGF), basic fibroblast growth factor (FGF-2) and factor VIII. RESULTS: Curative resection could be done in 4 patients (50%). Our data indicates a trend toward an association between complete resection and patient survival. Expression of p53, bcl-2, CEA, EMA, nm23-H1, VEGF and FGF-2 was detected in 5/8, 3/8, 4/8, 5/8, 6/8, 5/8 and 3/8, respectively. Mean Ki-67 labeling index and microvessel density was 7.01 and 34.36 (per 200× field), respectively. When compared with our previous studies, immunohistochemical staining of these proteins in thymomas, the expression rates of these proteins in thymic carcinomas were higher than those in thymomas. CONCLUSIONS: In this small series, it is suggested that a complete resection suggests a favorable result. Immunohistochemical results reveal that the expression of these proteins might indicate the aggressiveness of thymic carcinoma. BioMed Central 2002-05-23 /pmc/articles/PMC115847/ /pubmed/12049674 http://dx.doi.org/10.1186/1471-2482-2-3 Text en Copyright © 2002 Tomita et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.
spellingShingle Research Article
Tomita, Masaki
Matsuzaki, Yasunori
Edagawa, Masao
Maeda, Masayuki
Shimizu, Tetsuya
Hara, Masaki
Onitsuka, Toshio
Clinical and immunohistochemical study of eight cases with thymic carcinoma
title Clinical and immunohistochemical study of eight cases with thymic carcinoma
title_full Clinical and immunohistochemical study of eight cases with thymic carcinoma
title_fullStr Clinical and immunohistochemical study of eight cases with thymic carcinoma
title_full_unstemmed Clinical and immunohistochemical study of eight cases with thymic carcinoma
title_short Clinical and immunohistochemical study of eight cases with thymic carcinoma
title_sort clinical and immunohistochemical study of eight cases with thymic carcinoma
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC115847/
https://www.ncbi.nlm.nih.gov/pubmed/12049674
http://dx.doi.org/10.1186/1471-2482-2-3
work_keys_str_mv AT tomitamasaki clinicalandimmunohistochemicalstudyofeightcaseswiththymiccarcinoma
AT matsuzakiyasunori clinicalandimmunohistochemicalstudyofeightcaseswiththymiccarcinoma
AT edagawamasao clinicalandimmunohistochemicalstudyofeightcaseswiththymiccarcinoma
AT maedamasayuki clinicalandimmunohistochemicalstudyofeightcaseswiththymiccarcinoma
AT shimizutetsuya clinicalandimmunohistochemicalstudyofeightcaseswiththymiccarcinoma
AT haramasaki clinicalandimmunohistochemicalstudyofeightcaseswiththymiccarcinoma
AT onitsukatoshio clinicalandimmunohistochemicalstudyofeightcaseswiththymiccarcinoma